Increased serum concentrations of tissue inhibitor of metalloproteinase-1 in COPD patients Source: Eur Respir J 2005; 25: 885-890 Year: 2005
Impact of acute exposure to tobacco smoke on gelatinases in the bronchoalveolar space Source: Eur Respir J 2008; 32: 644-650 Year: 2008
Expression of matrix metalloproteinases and TIMP inhibitors in circulation/lung in patients with chronic obstructive pulmonary disease Source: Annual Congress 2012 - Asthma and COPD: understanding through mechanisms Year: 2012
The role of matrix metalloproteinase- 9 (MMP-9) and tissue inhibitor of matrix metalloproteinase-1 (TIMMP-1) in sarcoidosis and idiopathic pulmonary fibrosis. Correlation with echocardiography Source: Eur Respir J 2006; 28: Suppl. 50, 745s Year: 2006
Effect of the matrix metalloproteinase-9 on bone in chronic obstructive pulmonary disease Source: Annual Congress 2009 - Biomarkers and biology in COPD Year: 2009
Effect of recombinant α-1 antitrypsin (rAAT) and TAPI on neutrophil elastase (NE) and matrix metalloproteinase-9 (MMP9) activity in induced sputum (IS) from healthy smokers and patients with chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2003 - Progress on therapy for chronic obstructive pulmonary disease Year: 2003
Relationship between MMP-9 and TIMP-1 induced sputum concentration and the stage of chronic obstructive pulmonary disease‘s (COPD) Source: Annual Congress 2008 - Issues in the management of COPD in the community Year: 2008
Tissue inhibitor of metalloproteinases-2 gene polymorphisms in chronic obstructive pulmonary disease Source: Eur Respir J 2001; 18: Suppl. 33, 521s Year: 2001
Human macrophage elastase (MMP-12) expression in human emphysematous lungs: role in extracellular matrix remodelling in chronic obstructive pulmonary diseases (COPD) Source: Eur Respir J 2001; 18: Suppl. 33, 501s Year: 2001
Matrix metalloproteinases and tissue inhibitor of metalloproteinase-1 in sarcoidosis and IPF Source: Eur Respir J 2002; 20: 1220-1227 Year: 2002
Circulating matrix metalloproteinase-9 (MMP-9) is associated with the extension of lung disease in patients with active tuberculosis Source: Eur Respir J 2004; 24: Suppl. 48, 35s Year: 2004
Tissue inhibitor of metalloproteinases-;2 gene polymorphisms in chronic obstructive pulmonary disease Source: Eur Respir J 2001; 18: 748-752 Year: 2001
Gelatinase expression in pulmonary arteries during experimental pulmonary hypertension Source: Eur Respir J 2001; 18: 838-845 Year: 2001
Correlation of serum levels of matrix-metalloproteinase-9, cyclo-oxygenase-2, and prostaglandin-E-2 in Chronic obstructive pulmonary disease(COPD) Source: Virtual Congress 2021 – Biomarkers for the management of bronchial obstructive diseases Year: 2021
Matrix metalloproteinases, as markers of the severity of idiopathic pulmonary fibrosis Source: International Congress 2019 – Biomarkers of idiopathic interstitial pneumonia Year: 2019
Increased concentration of matrix metalloproteinase-9 in serum of COPD patients Source: Eur Respir J 2005; 26: Suppl. 49, 54s Year: 2005
Matrix metalloproteinase (MMP) 12 is associated with clinical parameters of disease severity and exacerbations in asthma Source: Annual Congress 2010 - Asthma: basic science and clinical studies Year: 2010
Matrix metalloproteinases and lung disease severity in chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2001; 18: Suppl. 33, 249s Year: 2001
Sputum matrix metalloproteinase-9 and tissue inhibitor of matrix metalloprotienase-1 levels in patients with COPD Source: Eur Respir J 2006; 28: Suppl. 50, 651s Year: 2006
Involvement of MMP-12 and phosphodiesterase type 4 in cigarette smoke-induced inflammation in mice Source: Eur Respir J 2006; 27: 1102-1109 Year: 2006